Management of type 2 diabetes mellitus: selecting the right of antihyperglycemic medication
https://doi.org/10.21518/2079-701X-2018-4-12-16
Abstract
The incidence of diabetes mellitus (DM) is steadily increasing. InRussia, as in many countries, diabetes is a socially significant disease, while patients with type 2 diabetes account for 85–90% of the total number of people with diabetes. The development of optimal treatment tactics for diabetes mellitus is now one of the most urgent tasks of modern medicine.
About the Author
E. V. Biryukova
Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of Russia
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
References
1. Standards of specialized medical care in diabetes. Edited by Dedov II, Shestakova MV, 8th Issue. M., 2017.
2. Bianchi C, Daniele G, Dardano A, Miccoli R, Del Prato S. Early Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes. Drugs, 2017, 77(3): 247-264.
3. Schernthaner G. Fixed-dose combination therapies in the management of hyperglycaemia in type 2 diabetes: an opportunity to improve adherence and patient care. Diabet Med, 2010, 27(7): 739-743.
4. Han S, Iglay K, Davies MJ, Zhang Q, Radican L. Glycemic effectiveness and medication adherence with fixed-dose combination or coadministered dual therapy of antihyperglycemic regimens: a meta-analysis. Curr Med Res Opin, 2012, 8(6): 969-977.
5. Liu Y, Hong T. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. Diabetes Obes Metab, 2014, 16(2): 111-117. doi: 10.1111/dom.12128. Epub 2013 Jun 3.
6. Wu D, Li L, Liu C. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Obes Metab, 2014, 16(1): 30-37. doi: 10.1111/dom.12174. Epub 2013 Jul 16.
7. Rojas LBA, Gomes MB. Metformin: an old but still the best treatment for type 2 diabetes. Diabetology & Metabolic Syndrome, 2013, 5: 6. doi.org/10.1186/1758-5996-5-6.
8. Markowicz-Piasecka M, Huttunen KM, Mateusiak L, Mikiciuk-Olasik E, Sikora J. Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics. Current Pharmaceutical Design, 2017, 23: 1-19.
9. Shinmura K, Negoro T, Shimizu S et al. Metformin modulates GLP-1and GIPmediated intracellular signaling under normoglycemic conditions. Open Journal of Endocrine and Metabolic Diseases, 2013, 3: 263-270.
10. Liu S-C et al. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes, Obesity and Metabolism, 2012, 14: 810-820.
11. Zhang Q et al. Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses. Diabetes Res Clin Pract, 2014 Sep, 105(3): 313-321. doi: 10.1016/j.diabres.2014.06.006. Epub 2014.
12. Ahrén B. Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2010, 3: 31-41.
13. Engel SS, Golm GT, Shapiro D et al. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc. Diabetol., 2013, 12(1): 3. www. cardiab.com/content/12/1/3.
14. Green JB, Bethel MA, Armstrong PW et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2015, 373(3): 232-242.
15. Paneni F, Costantino S, Cosentino F. Insulin resistance, diabetes, and cardiovascular risk. Curr Atheroscler Rep, 2014, 16(7): 419. doi: 10.1007/s11883-014-0419-z.
16. De Cosmo S, Menzaghi C, Prudente S, Trischitta V. Role of insulin resistance in kidney dysfunction: insights into the mechanism and epidemiological evidence. Nephrol Dial Transplant, 2013, 28: 29-36.
17. Johnson JA, Majumdar SR, Simpson SH. Decreased mortality associated with the use of metformin compared with sulfonylurea Monotherapy in type 2 diabetes. Diabetes Care, 2002, 25: 2244-2248.
18. Kao J, Tobis J, McClelland RL. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol, 2004, 93: 1347-1350. 10.1016/j.amjcard.2004.02.028.
Review
For citations:
Biryukova EV. Management of type 2 diabetes mellitus: selecting the right of antihyperglycemic medication. Meditsinskiy sovet = Medical Council. 2018;(4):12-16. (In Russ.) https://doi.org/10.21518/2079-701X-2018-4-12-16
Views:
835
Email this article 